Abstract

Cannabis has been legalised for medical use in an ever-increasing number of countries. A growing body of scientific evidence supports the use of medical cannabis for a range of therapeutic indications. In parallel with these developments, concerns have been expressed by many prescribers that increased use will lead to patients developing cannabis use disorder. Cannabis use disorder has been widely studied in recreational users, and these findings have often been projected onto patients using medical cannabis. However, studies exploring medical cannabis dependence are scarce and the appropriate methodology to measure this construct is uncertain. This article provides a narrative review of the current research to discern if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users. We focus on the main issues related to medical cannabis and dependence, including the importance of dose, potency, cannabinoid content, pharmacokinetics and route of administration, frequency of use, as well as set and setting. Medical and recreational cannabis use differs in significant ways, highlighting the challenges of extrapolating findings from the recreational cannabis literature. There are many questions about the potential for medical cannabis use to lead to dependence. It is therefore imperative to address these questions in order to be able to minimise harms of medical cannabis use. We draw out seven recommendations for increasing the safety of medical cannabis prescribing. We hope that the present review contributes to answering some of the key questions surrounding medical cannabis dependence.

Highlights

  • What lessons can we learn from history?Cannabis is arguably the world’s oldest medicine

  • We offer a narrative review of the literature and consider to what extent research on recreational cannabis dependence might be applied to medical cannabis dependence

  • We focus on cannabis-based medicinal products (CBMPs) as defined by the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018:

Read more

Summary

Introduction

Cannabis is arguably the world’s oldest medicine. It has been used medically for millennia especially in China and India. The medical use of cannabis in the West declined in the early 20th century, partly due to extreme variations in effects depending on where, how, when and what strain of plant material had been grown We understand these variations as deriving from different combinations and concentrations of over 140 cannabinoids and more than 100 different terpenoids found in different strains of the cannabis plant. It might differ in that some cannabinoids like tetrahydrocannabinol (THC) in higher doses and frequent usage promote dependence whilst cannabidiol (CBD), may have anti-addictive properties (Freeman et al, 2020; Morgan et al, 2010) This means that carefully balancing the cannabinoid content of cannabis-based medicines could potentially block the development of dependence. These are: 1. Two THC-based medicines: dronabinol – licensed for appetite loss in acquired immune deficiency syndrome (AIDS) and as an anti-emetic in chemotherapy and nabilone licensed for nausea in individuals receiving chemotherapy

CBD-based medicines
Discussion
Limitations and future research
Findings
Declaration of conflicting interests
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call